In this article AZN-GB BMY LLY NVS NOV.N-CH Skynesher | E+ | Getty Images Big pharma is betting billions on an up-and-coming class of cancer treatments that some on Wall Street are calling a "massive opportunity." It's called targeted radiopharmaceuticals. The therapy essentially delivers radiation directly into tumors by attaching a radioactive particle to a targeting molecule. RBC Capital Markets sees a $25 billion market opportunity for the space. "We believe TRT development is still in its early stages, ...